FDA 483 - Bio Products Laboratory Ltd - August 30, 2022

Bio Products Laboratory Ltd. in Elstree, United Kingdom, was cited for significant deficiencies during an FDA inspection from August 22-30, 2022. The observations primarily concern inadequate investigations into product failures, untimely reporting of biological product deviations, and critical failures in aseptic processing, environmental monitoring, and test method validation. These issues indicate a lack of adherence to established procedures and controls, potentially impacting product quality and patient safety.